Reducing safety-related drug attrition: The use of in vitro pharmacological profiling
Tools
Tools
Bowes, Joanne, Brown, Andrew J, Hamon, Jacques, Jarolimek, Wolfgang, Sridhar, Arun, Waldron, Gareth and Whitebread, Steven (2012) Reducing safety-related drug attrition: The use of in vitro pharmacological profiling. Nature Reviews Drug discovery, 11 (12). pp. 909-922. ISSN 1474-1776
Abstract
In vitro pharmacological profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved. Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacological profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process. We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.
| Item Type: | Article |
|---|---|
| Related URLs: | |
| Additional Information: | A large table of off-target annotations (attached as Excel file) will be included in the main body of the article. An expanded form of this table was previously included in a poster on this subject presented at a Safety Pharmacology Society Annual Meeting in Boston Sep. 2010; Can archive pre-print (ie pre-refereeing) |
| Keywords: | Drug Safety, in vitro, Pharmacology, Profiling, Review |
| Related URLs: | |
| Date Deposited: | 13 Oct 2015 13:14 |
| Last Modified: | 13 Oct 2015 13:14 |
| URI: | https://oak.novartis.com/id/eprint/6989 |